Trial reportAesthetic plastic surgery2026
Association of AbobotulinumtoxinA and Skinbooster for Periorbital Wrinkles: A Randomized, Controlled, Double-Blind, Split-Face Study.
Trial report in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough multimodal aesthetic treatments are used, the combined effects of botulinum toxin A and hyaluronic acid skinbooster for periorbital rejuvenation have not been properly evaluated. This study assessed the efficacy and durability of associating abobotulinumtoxinA and Restylane
methodsTwenty-four Brazilian women with dynamic periorbital wrinkles (Merz 5-point scale, levels II-IV) participated in this randomized, double-blinded, split-face trial. After bilateral abobotulinumtoxinA injections, one side of the face was randomized to receive Restylane
resultsEMG showed significant reductions over time, with no differences between treatments protocols (p > 0.05). For canthal wrinkle severity, the combined protocol (AbobotulinumtoxinA + Restylane® Skinbooster Vital) demonstrated lower scores at 3 months (p = 0.0001) and 6 months (p = 0.003) compared with AbobotulinumtoxinA alone, as reported by patients. Skin texture progressively improved following Restylane® Skinbooster Vital application, remaining significantly higher at 3 (p = 0.0001) and 6 months (p = 0.002) when compared with AbobotulinumtoxinA alone. Patient satisfaction increased in both protocols, with superior results at 3 months in the combined protocol group (p = 0.009).
conclusionThe association of abobotulinumtoxinA with Restylane® Skinbooster Vital provides enhanced and lasting improvements in severe canthal wrinkles. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.